Evidence map›Paper›PMID 39493325›Full record

ArticleWorld journal of gastroenterology2024

Anti-tumor efficacy of

Ishita Kathuria, Bhupesh Singla

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. World journal of gastroenterology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ishita KathuriaDepartment of Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, TN 38103, United States.
Bhupesh SinglaDepartment of Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, TN 38103, United States. bsingla@uthsc.edu.

Funding

Regulation of Lymphangiogenesis by Thrombospondin 1R00HL146954 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SINGLA, BHUPESH · 2022 to 2024
$739k
Regulation of Lymphangiogenesis by Thrombospondin 1K99HL146954 · NHLBI · AUGUSTA UNIVERSITY · PI SINGLA, BHUPESH · 2020 to 2021
$232k
NHLBI NIH HHS K99 HL146954NHLBI NIH HHS R00 HL146954
6 · The paper itself

Abstract

Despite significant advances in our understanding of the molecular pathogenesis of liver cancer and the availability of novel pharmacotherapies, liver cancer remains the fourth leading cause of cancer-related mortality worldwide. Tumor relapse, resistance to current anti-cancer drugs, metastasis, and organ toxicity are the major challenges that prevent considerable improvements in patient survival and quality of life.

Indexed as

Liver NeoplasmsTumor-Associated MacrophagesTumor MicroenvironmentAnimalsAntineoplastic AgentsCarcinoma, HepatocellularDrugs, Chinese HerbalHumansMiceWnt Signaling PathwayAntineoplastic AgentsDrugs, Chinese HerbalCalculus bovisLiver cancerM2-like tumor associated macrophagesTumor environmentWnt/β-catenin pathway

Identifiers

PMID39493325
PMCPMC11525873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.